DANHEART (H-HeFT and Met-HeFT)

• Status: Recruiting
• Trial end date: 2023-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The present study is testing in a combined design to types of drugs in patients with chronic heart failure: 1) Hydralazine in combination with isosorbide dinitrate (BiDil) and 2) Metformin hydrochloride. The study is double blind, placebo controlled.

1. The first hypothesis is that hydralazine in combination with isosorbide dinitrate can reduce mortality and hospitalization with worsening heart failure.

2. The second hypothesis is that treatment of underlying insulin resistance/ type 2 diabetes with metformin in heart failure patients with moderately to severely reduced LVEF can reduce mortality and cardiovascular hospitalizations. Among secondary endpoints are reduction in new-onset diabetes in heart failure patients with insulin resistance and diabetes risk profile and patient safety.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Henrik Wiggers
• Collaborators: Danish Council for Independent Research; Danish Heart Foundation; The Aase og Ejnar Danielsen Foundation; The Danish Regions: Foundation for Medical Research; The Novo Nordisk Foundation
• Treatments: Hydralazine; Isosorbide; Isosorbide Dinitrate; Isosorbide-5-mononitrate; Metformin

Criteria

Inclusion Criteria:

General inclusion criteria for both H-HeFT and Met-HeFT

• Patients with chronic heart failure

• NYHA-class II, III or IV

• LVEFperformed after uptitration in heart failure medication and (ii) LVEF from the most recently performed echocardiographic study should be used and (iii) LVEF must not be measured during rapid atrial fibrillation, i.e. heart rate >110/min) and (iiii) the echocardiography should be performed at least 3 months after CRT-implantation.

• Patients should be uptitrated to recommended or maximally tolerated dose of ACE-I/ARB/ARNI (unless contraindicated) and beta-blocker (unless contraindicated). If indicated, an aldosterone receptor antagonist should be given (unless contraindicated).

• A CRT device should be implanted, if indicated and accepted by the patient and patients with a CRT device should be treated for > 3 months.

• Implantation of an ICD unit should be planned or already done, if indicated and accepted by the patient. The patient can be included in the study before a planned ICD implantation has been performed.

• Informed consent

Specific inclusion criteria for only H-HeFT:

• Systolic blood pressure ≥100 mmHg

• NT-proBNP > 350 pg/ml or BNP > 80 pg/ml (in patients treated with ARNI, NT-proBNP must be used)

Specific inclusion criteria for only Met-HeFT:

Patients must have a diagnosis of type 2 diabetes or insulin resistance or diabetes risk. This includes 1 or more of any of the following:

• A previous diagnosis of type 2 diabetes at any time without Metformin treatment during the last 3 months

• HbA1c ≥ 5.5 % (≥ 37 mmol/mol) within 12 months prior to screening

• Fasting P-glucose ≥ 5.6 mmol/l within 12 months prior to screening (measured when the patient in stable condition / has no intercurrent illness)

• Body mass index ≥ 30 kg/m2

• If oral glucose tolerance testing (OGTT) has been performed at any time prior to randomization: 2 hour P-glucose ≥ 7.8 mmol/l

• In addition, patients in Met-HeFT must have eGFR ≥ 35 ml/min (MDRD)

Patients are randomized through an internet based randomization module. Patients can be allocated to a) both H-HeFT and Met-HeFT or to b) only H-HeFT or to c) only Met-HeFT.